key: cord-0875952-grx9l4fw
authors: Falahi, Shahab; Kenarkoohi, Azra
title: COVID-19 re-infection: prolonged shedding or true reinfection
date: 2020-11-12
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2020.100812
sha: e737680153d6230f89e693d30b165f428df5cae1
doc_id: 875952
cord_uid: grx9l4fw

The SARS-CoV-2 pandemic is underway and millions of people have been infected. A large number of patients with COVID-19 have recovered and been discharged. While a number of recovered patients test positive again or even have a recurrence of clinical symptoms. Some researchers believe that a positive retest is related to the long-term persistence of the virus in the body, although there is some evidence in favor of reinfection. In this study, we focus more on the possible reasons for positive retesting, antibody responses, and review of possible reinfection case reports.

Re-Positive PCR for COVID-19 raises many questions: does SARS-CoV-2 persist or reinfection occurs? However, if the reinfection is correct, controlling the pandemic will be very complicated and herd immunity to the vaccine or natural infection will be challenged.

SARS-CoV-2 reinfection has not yet been fully clarified. There are numerous reports that a number of patients tested positive again after two consecutive negative PCR tests or after clinical recovery (1, 2) . In some studies, they are attributed to the PCR false negative results at discharge, SARS-CoV-2 long-term shedding and increased virus replication as a result of discontinuation of the drug after clinical symptoms recovery (1, 3, 4) . In one study, it was suggested that positive retesting in recovered patients could be related to dead viruses and viral genomic fragments (5) .

On the other hand, there is evidence in favor of reinfection that should be considered. A distinction must be made between prolonged shedding/reactivation and true re-infection. True reinfection has criteria that must be considered, including isolation of the complete genome of the virus and not just genomic fragments in the second episode, sometimes a positive PCR test may be related to traces of RNA genomic, identification of two different viral strains in two episodes of infection based on phylogenetic analysis, proof of virus infectivity in the second episode by virus culture and evaluation of its cytopathic effect in cell culture, investigation of immune responses and their comparison in two episodes and epidemiological data such as re-exposure history to COVID-19 patient in the second event and timing between the episodes, the longer the time interval between two episodes in favor of reinfection hypothesis (3, 6) . The maximum duration of SARS-CoV-2 RNA shedding in the upper respiratory tract was 83 days (7) . Therefore, positive retesting more than 83 days after the first positive test, along with other criteria, is in favor of confirming reinfection. In addition to the aforementioned reasons, the clinical data of the disease are also useful in confirming the second episode, although the second episode may be asymptomatic. Clinical signs free time interval between two episodes is also necessary.

One of the features of SARS-CoV-2 infection is prolonged viral shedding. On the other hand, the sensitivity of PCR test to diagnose infection is not high and may cause false negative results(1) .

In addition, in a number of patients, stool samples are still positive after respiratory samples have become negative, indicating prolonged shedding of the virus in the gastrointestinal tract in the course of infection (1, 8, 9) . Also, it has been hypothesized that the gastrointestinal tract may act as a "reservoir" for SARS-CoV-2 even after tests on upper respiratory tract samples become negative (1) . Since the main criteria for discharge is the improvement of clinical symptoms and 2 negative PCR tests, it is recommended to modify the discharge criteria, due to the long-term shedding or later clearance of the SARS-CoV-2in the gastrointestinal tract compared to the upper respiratory tract (7, 9) . According, SARS-CoV-2 RNA can persist in stool specimens for approximately 5 weeks after patients' respiratory swabs have become negative (4, 10) and fecal specimen should be tested at the time of discharge. Adding a fecal specimen test at discharge partially alleviates the false negative test results, in turn this modification can help to discriminate between long-term virus shedding and true reinfection.

Humoral immune responses are the first line of defense against reinfection and the strength and durability of these responses is related to protection (11) . The dynamics of antibody responses in COVID-19 patients is not fully understood. In one study, the overall seroconversion rate was reported to be 96.8%, but their neutralizing activity and shelf life were not fully understood (12) .

Similarly, in the study of Zhao et al., the overall rate of seroconversion was 100% by day 39 after the onset of the disease, but in this study, further follow-up was not performed to evaluate the shelf life (13) . Consistent with the above studies, in another study, serum samples from 42 

There are limited studies on reinfection but they have raised many questions. One of the opposite studies of reinfection is related to an animal model(16) that their results showed the initial infection of SARS-CoV-2 provided protection against SARS-CoV-2 re-exposure and reinfection did not occur. Virus replication in monkeys' noses, lungs, and intestine was observed 5 days post-infection. Then, after the symptoms improved, the monkeys were re-exposed to the same dose of the SARS-CoV-2 again, no recurrence of the infection was seen in monkeys. Although, there are limited reports of reinfection that more focus should be on them:

In a case report in Hong Kong, a 33-year-old immunocompetent patient, 142 days after the first positive PCR test, was identified re-positive nucleic acid test again in an airport screening. In during first episode, patient has fever, cough, sputum production and headache but was asymptomatic in the second episode. The second PCR test was positive on August 15, 2020. He was hospitalized on August 16, 2020. The CRP protein was slightly elevated and the patient had hypokalemia. Serum samples were negative for Anti-SARS-CoV-2 IgG 10 days after the symptoms onset in the first episode and 1 to 3 days after hospitalization in second episode, and IgG seroconversion was observed from the fifth day after hospitalization in second event. The patient had two different virus strains in 2 episodes of infection (17) . Laboratory parameters in second stage, IgG seroconversion, increased CRP, and identification of two different viral clades J o u r n a l P r e -p r o o f in during 2 events are pieces of evidence that support the reinfection hypothesis. In addition, the relatively long time interval between the two events is also in favor of reinfection. Virus culture was ongoing at the time of publication.

In similarly, another study in the United States diagnosed a second infection 140 days after primary infection in July. First infection was in March. The patient was symptomatic in both stages, laboratory and radiographic findings showed that disease severity in the second stage was less than the first stage. About 140 days after the primary infection and recovery, the patient was exposed to people who had a cough. After that, the patient suffered from dyspnea, cough and weakness, this is followed by a positive re-test for COVID-19. The patient recovers with remdesivir and dexamethasone. Genomic analysis showed that viral strains isolated in the two distinct episodes were not the same. The strain isolated in March was similar to the strain imported from Asia, while the July strain had a D614G mutation that was similar to European strain. The time interval between two infections was consistent with a dominant strain change in the United States (D614G circulated in July as dominant strain) that supported the reinfection hypothesis versus intra-host viral evolution. Epidemiological data (history of exposure to people with cough), clinical features, laboratory findings, phylogenetic data were all in favor of reinfection. Humoral immune responses were also examined and it was concluded that poor humoral immune responses or their decrease over time is one of the reasons that a person may be infected with SARS-CoV-2 multiple times (18) .

In another case report, the patient was a 46-year-old man who had symptoms on May 12 and tested positive for PCR on May 20, 2020 and turned into negative on June 3, 2020. In late July, he had close contact with patient COVID-19 and two days later he became symptomatic. A few days after the onset of symptoms, the test was positive again on July 22, 2020.The patient had symptoms in both episodes, although the second episode was more severe. The viral strains belonged to two different clades, IgG/IgM antibodies was evaluated on May 16,2020, IgM was positive and IgG was negative in the first infection. Both IgM and IgG antibodies were detected in the second infection (19) . Evidence such as epidemiological data, clinical findings, positive PCR retest, 2 different viral clades and antibody responses were compatible with reinfection.

One of the limitations of this study was that the virus culture was not performed. Therefore, these populations are susceptible to reinfection (20) .

In accordance with the above studies, the first case of reinfection in Turkey was described as follows: a 23-year-old woman who had two symptomatic episodes 116 days apart. Although the authors claimed reinfection, the study had several drawbacks: genomic analysis was not performed, antibodies were not screened in the first infection. Antibodies in the second episode about 24 days after the symptoms onset were slightly positive (21) .

In confirmation of the reinfection, India also published cases of reinfection, Gupta V et al.

reported possible 2 re-infection patients in India (22) . The patients were health care workers who were identified in a routine screening of health care workers and were asymptomatic in both episodes. The interval between the two episode in each case was more than 3 months. In each episode, a different viral strain was detected, but antibody analysis and virus culture were not performed.

In conclusion, some researchers believe that retesting positive for SARS-CoV-2 may be explained by reactivation or relapse of the infection and other groups emphasize the reinfection hypothesis. In fact, retest positive for SARS-CoV-2 should be interpreted correctly because there are several reasons, such as false-negative test results at discharge, prolonged shedding of the virus, virus replication's rebound after drug discontinuation and reinfection. According to the reported cases and the evidence confirming the reinfection, reinfection may occur but the incidence is low. However, its rate may also be underestimated due to asymptomatic infections in one or both episodes.

We thank all the healthcare staff involved in diagnosing COVID -19 disease. We did not receive funding for this study.

There is no conflict of interest.

Re-detectable positive SARS-CoV-2 RNA tests in patients who recovered from COVID-19 with intestinal infection

Positive RT-PCR test results in patients recovered from COVID-19

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound

Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again

Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection?

European Centre for Disease Prevention and Control. Reinfection with SARS-CoV: considerations for public health response

SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and metaanalysis. medRxiv

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Antibody responses against SARS-CoV-2 in COVID-19 patients

Antibody responses to SARS-CoV-2 in patients with COVID-19

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal transduction and targeted therapy

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report

COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

Covid-19 Re-Infection: First Report from Turkey. New Microbes and New Infections

Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2

J o u r n a l P r e -p r o o f